17,682 Shares in Insmed Incorporated (NASDAQ:INSM) Acquired by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. acquired a new stake in Insmed Incorporated (NASDAQ:INSM - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 17,682 shares of the biopharmaceutical company's stock, valued at approximately $1,291,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. V Square Quantitative Management LLC acquired a new position in shares of Insmed in the 3rd quarter valued at about $30,000. GAMMA Investing LLC lifted its stake in shares of Insmed by 71.3% in the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 224 shares in the last quarter. First Horizon Advisors Inc. lifted its stake in shares of Insmed by 83.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 287 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in shares of Insmed by 522.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company's stock valued at $55,000 after purchasing an additional 627 shares in the last quarter. Finally, EntryPoint Capital LLC acquired a new position in Insmed during the 1st quarter worth approximately $33,000.

Insmed Trading Up 5.1 %

Shares of Insmed stock traded up $3.56 during trading on Wednesday, hitting $72.86. The stock had a trading volume of 2,178,302 shares, compared to its average volume of 1,149,379. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The business has a fifty day moving average of $72.66 and a two-hundred day moving average of $62.45. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $80.53.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. During the same period last year, the business posted ($1.10) EPS. The firm's revenue for the quarter was up 18.1% on a year-over-year basis. As a group, analysts anticipate that Insmed Incorporated will post -5.52 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on INSM shares. TD Cowen boosted their price target on Insmed from $75.00 to $98.00 and gave the stock a "buy" rating in a research report on Friday, August 9th. Cantor Fitzgerald reissued an "overweight" rating on shares of Insmed in a research report on Monday, September 9th. HC Wainwright reissued a "buy" rating and set a $90.00 price target on shares of Insmed in a research report on Friday, November 1st. Truist Financial reissued a "buy" rating and set a $105.00 price target (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. Finally, Bank of America boosted their price target on Insmed from $84.00 to $86.00 and gave the stock a "buy" rating in a research report on Wednesday, October 9th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat, Insmed currently has a consensus rating of "Moderate Buy" and an average target price of $83.07.

Insider Activity

In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the company's stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the transaction, the insider now directly owns 100,100 shares of the company's stock, valued at approximately $7,157,150. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Insmed news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the company's stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total value of $2,686,612.50. Following the transaction, the insider now directly owns 100,100 shares of the company's stock, valued at $7,157,150. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Michael Alexander Smith sold 27,871 shares of the stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $74.35, for a total value of $2,072,208.85. Following the transaction, the insider now directly owns 67,856 shares in the company, valued at approximately $5,045,093.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 78,882 shares of company stock valued at $5,765,446 over the last three months. Insiders own 4.60% of the company's stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.